======= CNOT2 =======
== Gene Information ==
* **Official Symbol**: CNOT2
* **Official Name**: CCR4-NOT transcription complex subunit 2
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=4848|4848]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q9NZN8|Q9NZN8]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=CNOT2&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20CNOT2|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/604909|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Component of the CCR4-NOT complex which is one of the major cellular mRNA deadenylases and is linked to various cellular processes including bulk mRNA degradation, miRNA-mediated repression, translational repression during translational initiation and general transcription regulation. Additional complex functions may be a consequence of its influence on mRNA expression. Required for the CCR4-NOT complex structural integrity. Can repress transcription and may link the CCR4-NOT complex to transcriptional regulation; the repressive function may specifically involve the N-Cor repressor complex containing HDAC3, NCOR1 and NCOR2. Involved in the maintenance of emryonic stem (ES) cell identity. {ECO:0000269|PubMed:14707134, ECO:0000269|PubMed:16712523, ECO:0000269|PubMed:21299754, ECO:0000269|PubMed:22367759}.
|NOT2 3 5|
|RNA polymerase II transcription corepressor binding|
|positive regulation of cytoplasmic mRNA processing body assembly|
|CCR4-NOT core complex|
|regulation of cytoplasmic mRNA processing body assembly|
|poly(A)-specific ribonuclease activity|
|negative regulation of intracellular estrogen receptor signaling pathway|
|trophectodermal cell differentiation|
|CCR4-NOT complex|
|nuclear-transcribed mRNA poly(A) tail shortening|
|regulation of stem cell population maintenance|
|negative regulation of intracellular steroid hormone receptor signaling pathway|
|blastocyst formation|
|regulation of intracellular estrogen receptor signaling pathway|
|RNA phosphodiester bond hydrolysis, exonucleolytic|
|DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest|
|intracellular signal transduction involved in G1 DNA damage checkpoint|
|signal transduction involved in mitotic cell cycle checkpoint|
|signal transduction involved in mitotic G1 DNA damage checkpoint|
|signal transduction involved in mitotic DNA damage checkpoint|
|signal transduction involved in mitotic DNA integrity checkpoint|
|nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay|
|mitotic G1 DNA damage checkpoint|
|mitotic G1/S transition checkpoint|
|G1 DNA damage checkpoint|
|signal transduction involved in DNA integrity checkpoint|
|signal transduction involved in DNA damage checkpoint|
|signal transduction involved in cell cycle checkpoint|
|positive regulation of organelle assembly|
|regulation of intracellular steroid hormone receptor signaling pathway|
|DNA damage response, signal transduction by p53 class mediator|
|positive regulation of cell cycle arrest|
|transcription coregulator activity|
|P-body|
|gene silencing by RNA|
|mitotic DNA damage checkpoint|
|blastocyst development|
|negative regulation of G1/S transition of mitotic cell cycle|
|mitotic DNA integrity checkpoint|
|signal transduction in response to DNA damage|
|negative regulation of cell cycle G1/S phase transition|
|regulation of cell cycle arrest|
|signal transduction by p53 class mediator|
|negative regulation of translation|
|DNA damage checkpoint|
|DNA integrity checkpoint|
|negative regulation of cellular amide metabolic process|
|regulation of G1/S transition of mitotic cell cycle|
|gene silencing|
|mitotic cell cycle checkpoint|
|RNA phosphodiester bond hydrolysis|
|regulation of cell cycle G1/S phase transition|
|cell cycle checkpoint|
|nuclear-transcribed mRNA catabolic process|
|negative regulation of mitotic cell cycle phase transition|
|mRNA catabolic process|
|regulation of organelle assembly|
|negative regulation of cell cycle phase transition|
|RNA catabolic process|
|positive regulation of protein complex assembly|
|positive regulation of cell cycle process|
|nucleic acid phosphodiester bond hydrolysis|
|negative regulation of mitotic cell cycle|
|negative regulation of cell cycle process|
|regulation of translation|
|nucleobase-containing compound catabolic process|
|positive regulation of cell cycle|
|in utero embryonic development|
|regulation of cellular amide metabolic process|
|regulation of mitotic cell cycle phase transition|
|heterocycle catabolic process|
|cellular nitrogen compound catabolic process|
|aromatic compound catabolic process|
|regulation of cell cycle phase transition|
|regulation of protein complex assembly|
|organic cyclic compound catabolic process|
|positive regulation of cellular component biogenesis|
|posttranscriptional regulation of gene expression|
|negative regulation of cell cycle|
|mitotic cell cycle process|
|positive regulation of organelle organization|
|regulation of mitotic cell cycle|
|chordate embryonic development|
|embryo development ending in birth or egg hatching|
|mitotic cell cycle|
|mRNA metabolic process|
|regulation of cell cycle process|
|cellular response to DNA damage stimulus|
|negative regulation of transcription by RNA polymerase II|
|anatomical structure formation involved in morphogenesis|
|cellular macromolecule catabolic process|
|regulation of cellular component biogenesis|
|embryo development|
|cell cycle process|
|negative regulation of cellular protein metabolic process|
|macromolecule catabolic process|
|negative regulation of protein metabolic process|
|regulation of cell cycle|
|negative regulation of transcription, DNA-templated|
|positive regulation of cellular component organization|
|negative regulation of nucleic acid-templated transcription|
|negative regulation of RNA biosynthetic process|
|negative regulation of signal transduction|
|regulation of organelle organization|
|negative regulation of RNA metabolic process|
|cell cycle|
|negative regulation of cell communication|
|negative regulation of signaling|
|negative regulation of cellular macromolecule biosynthetic process|
|negative regulation of nucleobase-containing compound metabolic process|
|negative regulation of macromolecule biosynthetic process|
|negative regulation of cellular biosynthetic process|
|negative regulation of biosynthetic process|
|negative regulation of response to stimulus|
|RNA metabolic process|
|intracellular signal transduction|
|cellular response to stress|
|negative regulation of gene expression|
|organic substance catabolic process|
|cellular catabolic process|
|membrane|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|-4.63|
|[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|-4.56|
|[[:results:exp7|Bortezomib 0.05μM R00 exp7]]|-3.8|
|[[:results:exp535|Trimetrexate 0.03μM R08 exp535]]|-3.36|
|[[:results:exp46|HMS-I1 1μM R01 exp46]]|-3.25|
|[[:results:exp460|BML-284 0.09μM R08 exp460]]|-3.23|
|[[:results:exp21|MLN-4924 0.2μM R00 exp21]]|-3.05|
|[[:results:exp416|Tubacin 1.6μM R07 exp416]]|-3.04|
|[[:results:exp17|DABN 20μM R00 exp17]]|-3|
|[[:results:exp3|Actinomycin-D 0.001μM R00 exp3]]|-2.95|
|[[:results:exp78|Pterostilbene 16μM R02 exp78]]|-2.91|
|[[:results:exp517|Quercetin 20μM R08 exp517]]|-2.87|
|[[:results:exp59|UMK57 1μM R01 exp59]]|-2.83|
|[[:results:exp84|UM0125461 0.74μM R02 exp84]]|-2.75|
|[[:results:exp356|Docosahexaenoic-acid 50μM R07 exp356]]|-2.72|
|[[:results:exp103|Taxol 0.004μM R03 exp103]]|-2.71|
|[[:results:exp226|Cerivastatin 0.15μM R05 exp226]]|-2.69|
|[[:results:exp19|Etoposide 1μM R00 exp19]]|-2.67|
|[[:results:exp497|Lead acetate 2000μM R08 exp497]]|-2.67|
|[[:results:exp2|5-Fluorouracil 20μM R00 exp2]]|-2.64|
|[[:results:exp330|5-Azacytidine 2μM R07 exp330]]|-2.62|
|[[:results:exp436|Dynasore 7μM R08 exp436]]|-2.61|
|[[:results:exp60|Vinblastine 0.002μM R01 exp60]]|-2.56|
|[[:results:exp312|2-Methoxyestradiol 0.55 to 1μM on day4 R07 exp312]]|-2.51|
|[[:results:exp89|Vemurafenib 6.6μM R02 exp89]]|-2.48|
|[[:results:exp190|Vincristine 0.0005μM R04 exp190]]|-2.46|
|[[:results:exp498|Lead acetate 2000μM R08 exp498 no dilution day6]]|-2.41|
|[[:results:exp533|TNF-alpha 44ng/ml R08 exp533]]|-2.41|
|[[:results:exp66|BI-D1870 3.15μM R02 exp66]]|-2.4|
|[[:results:exp22|MLN-4924 2μM R00 exp22]]|-2.4|
|[[:results:exp451|Atovaquone 15μM R08 exp451]]|-2.37|
|[[:results:exp216|Erlotinib 10μM R05 exp216]]|-2.37|
|[[:results:exp290|LLY-283 2.6μM R06 exp290]]|-2.33|
|[[:results:exp354|Diepoxybutane 3μM R07 exp354]]|-2.32|
|[[:results:exp329|Hydroxyurea 100μM R07 exp329]]|-2.32|
|[[:results:exp228|Demecolcine 0.03μM R05 exp228]]|-2.3|
|[[:results:exp199|Etoposide 0.3μM R05 exp199]]|-2.26|
|[[:results:exp310|2-Methoxyestradiol 0.55μM R07 exp310]]|-2.23|
|[[:results:exp271|CCT251545 0.2μM R06 exp271]]|-2.23|
|[[:results:exp107|UMK57 0.6μM R03 exp107]]|-2.23|
|[[:results:exp360|Genistein 15μM R07 exp360]]|-2.22|
|[[:results:exp215|Colchicine 0.009μM R05 exp215]]|-2.21|
|[[:results:exp520|Rucaparib 6.5μM R08 exp520]]|-2.21|
|[[:results:exp75|MK-1775 0.32μM R02 exp75]]|-2.2|
|[[:results:exp431|Rotenone 0.07μM R08 exp431]]|-2.17|
|[[:results:exp242|Radicicol 0.16μM R05 exp242]]|-2.16|
|[[:results:exp28|Pimelic-diphenylamide-106 5μM R00 exp28]]|-2.14|
|[[:results:exp299|Talazoparib 0.006μM R06 exp299]]|-2.14|
|[[:results:exp217|Mdivi-1 15μM R05 exp217]]|-2.12|
|[[:results:exp441|GSK-J4 1.5μM R08 exp441]]|-2.07|
|[[:results:exp26|Oligomycin-A 20μM R00 exp26]]|-2.06|
|[[:results:exp230|Epigallocatechin gallate 20μM R05 exp230]]|-2.05|
|[[:results:exp483|FTY720 3μM R08 exp483]]|-2.05|
|[[:results:exp162|BI-D1870 2μM R04 exp162]]|-2.03|
|[[:results:exp67|BVD-523 15μM R02 exp67]]|-2.02|
|[[:results:exp472|CI-1040 9.5μM R08 exp472]]|-2.02|
|[[:results:exp474|CR131-b 0.005μM R08 exp474]]|-2.01|
|[[:results:exp512|Olaparib 4μM R08 exp512]]|-2|
|[[:results:exp34|Rotenone 20μM R00 exp34]]|-1.99|
|[[:results:exp184|Ixabepilone 0.004 to 0.005μM on day4 R04 exp184]]|-1.98|
|[[:results:exp468|CB-5083 0.4μM R08 exp468]]|-1.92|
|[[:results:exp164|Q15 1 to 2μM on day4 R04 exp164]]|-1.9|
|[[:results:exp311|2-Methoxyestradiol 0.55 to 0.75μM on day4 R07 exp311]]|-1.89|
|[[:results:exp503|Mitomycin-C 0.06μM R08 exp503]]|-1.88|
|[[:results:exp350|Deferoxamine 11μM R07 exp350]]|-1.81|
|[[:results:exp449|Arsenic trioxide 60μM R08 exp449]]|-1.79|
|[[:results:exp211|AICAR 240μM R05 exp211]]|-1.76|
|[[:results:exp96|BI-2536 0.02μM R03 exp96]]|-1.76|
|[[:results:exp95|BI-2536 0.0042μM R03 exp95]]|-1.76|
|[[:results:exp48|Mubritinib 0.2μM R01 exp48]]|-1.75|
|[[:results:exp301|VER-155008 3.9μM R06 exp301]]|-1.73|
|[[:results:exp128|GSK591 2.6μM R03 exp128]]|-1.72|
|[[:results:exp446|4-Nitroquinoline-1-oxide 0.5μM R08 exp446]]|-1.71|
|[[:results:exp33|Rotenone 2μM R00 exp33]]|-1.71|
|[[:results:exp272|CHIR-124 0.04μM R06 exp272]]|1.73|
|[[:results:exp405|Tenofovir 10μM R07 exp405]]|1.85|
|[[:results:exp115|A-366 10μM R03 exp115]]|2.06|
|[[:results:exp100|NFN1 1μM R03 exp100]]|2.06|
|[[:results:exp153|SGC2096 2.6μM R03 exp153]]|2.07|
|[[:results:exp274|Citral 50μM R06 exp274]]|2.15|
|[[:results:exp222|Betulinic acid 10 to 15μM on day4 R05 exp222]]|2.33|
|[[:results:exp18|Doxycycline 10μM R00 exp18]]|2.53|
|[[:results:exp308|Rapamycin 2μM plus FK-506 5μM R07 exp308]]|2.64|
|[[:results:exp248|UM0131023 0.05μM R05 exp248]]|3.05|
|[[:results:exp234|Ethanol 0.01 R05 exp234]]|3.15|
|[[:results:exp504|MK2206 4μM R08 exp504]]|3.43|
|[[:results:exp29|Rapamycin 1μM R00 exp29]]|3.46|
|[[:results:exp30|Rapamycin 10μM R00 exp30]]|3.68|
|[[:results:exp429|Rapamycin 0.001μM R08 exp429]]|3.89|
|[[:results:exp306|Rapamycin 2μM R07 exp306]]|5.19|
^Gene^Correlation^
|[[:human genes:c:cnot3|CNOT3]]|0.569|
|[[:human genes:p:pds5b|PDS5B]]|0.563|
|[[:human genes:c:cnot8|CNOT8]]|0.481|
|[[:human genes:c:cwc27|CWC27]]|0.476|
|[[:human genes:c:cdk8|CDK8]]|0.461|
|[[:human genes:a:arid4b|ARID4B]]|0.46|
|[[:human genes:a:anp32a|ANP32A]]|0.46|
|[[:human genes:k:kdm6a|KDM6A]]|0.457|
|[[:human genes:e:esco1|ESCO1]]|0.456|
|[[:human genes:f:fam122a|FAM122A]]|0.448|
|[[:human genes:p:pcgf1|PCGF1]]|0.434|
|[[:human genes:y:ypel5|YPEL5]]|0.419|
|[[:human genes:f:fkbp1a|FKBP1A]]|0.418|
|[[:human genes:w:wdr26|WDR26]]|0.416|
|[[:human genes:t:tsc2|TSC2]]|0.414|
|[[:human genes:m:memo1|MEMO1]]|0.409|
|[[:human genes:d:depdc5|DEPDC5]]|0.402|
Global Fraction of Cell Lines Where Essential: 21/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|1/28|
|blood|0/28|
|bone|1/26|
|breast|2/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|1/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|3/75|
|lymphocyte|0/16|
|ovary|1/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|1/1|
|skin|3/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|1/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 16805
* **Expression level (log2 read counts)**: 6.57
{{:chemogenomics:nalm6 dist.png?nolink |}}